1. MAPK pathway activity plays a key role in programmed death ligand-1 expression of EGFR wild-type non-small cell lung adenocarcinoma cells

   Stutvoet, T., Kol, A., de Vries, E., de Bruyn, M., Fehrmann, R., van Scheltinga, A. T. & de Jong, S., Nov-2018, p. E78-E79. 2 p.

   Research output: Contribution to conference › Poster › Academic

2. A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

   Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., Van Gool, I. C., Eggink, F. A., Wouters, M. C., Komdeur, F. L., van der Slikke, E. C., Creutzberg, C. L., Kol, A., Plat, A., Glaire, M., Church, D. N., Nijman, H. W. & de Bruyn, M., 2019, In : Cancer immunology research. 38 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Preclinical evaluation and molecular imaging of HER family dynamics to guide cancer therapy

   Kol, K. J-D., 2019, [Groningen]: Rijksuniversiteit Groningen. 175 p.

   Research output: Thesis › Thesis fully internal (DIV) › Academic

4. (89)Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment

   Pool, M., Kol, A., de Jong, S., de Vries, E. G. E., Lub-de Hooge, M. N. & Terwisscha van Scheltinga, A. G. T., 2017, In : mAbs. 9, p. 1370-1378 9 p.

   Research output: Contribution to journal › Article › Academic › peer-review

5. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells

   Kol, A., Terwisscha van Scheltinga, A., Pool, M., Gerdes, C., de Vries, E. & de Jong, S., 11-Jul-2017, In : Oncotarget. 8, 28, p. 45432-45446 15 p.

   Research output: Contribution to journal › Article › Academic › peer-review

View all (9) »